Table 2 Response and potential biomarkers of patients with anaplastic thyroid cancer who received lenvatinib and pembrolizumab as first-line therapy
| Â | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|---|---|---|---|---|---|
Best overall response | SD | PR | not evaluable | SD | SD |
Time on therapy, months | 2.1 | 3.5 | ongoing (12.7 +) | 0.8 | 4.2 |
Progression-free survival, months | 5.9 | 5.1 | not evaluable | 0.8 | 4.2 |
Overall survival, months | 6.3 | 9.6 | ongoing (12.7 +) | 0.8 | 4.2 |
Histopathology | |||||
 Ki-67, % | 80 | 26 | 60 | 70 | 30 |
 PD-L1, % | |||||
 PD-L1 TPS | 15 | 90 | 90 | 10 | 90 |
 PD-L1 IC | 5 | 0 | 20 | 2 |  < 1 |
 PD-L1 CPS | 20 | 90 | 100 | 12 | 90 |
 DNA mismatch repair status | pMMR | pMMR | dMMR (MLH1- PMS2-)* | pMMR | pMMR |
 TILs (CD3 +), % | 4.4 | 31.4 | 14.2 | 30.0 | 4.0 |
 CD8 + of TILs, % | 72.1 | 33.8 | 95.7 | 60.7 | 42.9 |
 TAMs (CD68 +), % | 40.2 | 35.2 | 21.3 | 37.4 | 31.8 |
Molecular pathology, % allele frequency | OFA | OFA | QIAseq Targeted Panel | OFA | OFA |
 BRAF p.V600E | - | 6 | - | - | 10 |
 KRAS p.G12R | - | - | 53 | - | - |
 TP53 p.P153fs | - | - | 56 | - | - |
 PIK3CA p.E545K | - | - | - | - | 7 |
Lenvatinib starting dosage, mg | 14 | 24 | 24 | 24 | 14 |